TargetRx Atlas

MRNA basic information

  • mRNA ID:ENST00000242261
  • Gene Name:TWIST1
  • mRNA database:Ensembl
  • mRNA expression :up-regulated
  • mRNA Method:qRT-PCR
  • mRNA Pathway:NA
  • Evidence:predicted
  • (mRNA-drug)

Drug basic information

  • Drug ID:NA
  • Drug Name:NA
  • Drug Method:NA

Disease basic infommation

  • Disease:ovarian cancer
  • Tissue:Human ovarian cancer cell lines (A2780, OV2008, OVCAR3, SKOV3 and CAOV3), the related cDDP-resistant cell lines (ACRP, C13* and OVCAR3/ DDP), a human breast cancercell line (MCF-7) and the ADM-resistant cell line (MCF-7/ADM)

Other information

  • Title:miR-186 regulation of Twist1 and ovarian cancer sensitivity to cisplatin.
  • Journal:Oncogene
  • Published:2016
  • PubMed ID:25867064
  • Abstract:Epithelial-mesenchymal transition (EMT) has an established role in promoting tumor progression and the acquisition of therapeutic resistance. Here, the EMT phenotype was detected in cisplatin-resistant ovarian cancer tissues and cell lines, and correlated with decreased miR-186 expression, increased Twist1 expression, chemoresistance and poor prognosis in epithelial ovarian cancer (EOC) patients. Introducing miR-186 into EOC cells led to a reduction in twist family bHLH transcription factor 1 (Twist1) expression along with morphological, functional and molecular changes consistent with mesenchymal-to-epithelial transition, G1 cell-cycle arrest and enhanced cell apoptosis, which consequently rendered the cells more sensitive to cisplatin in vitro and in vivo. Furthermore, luciferase reporter and rescue assay results showed that the EMT and drug resistance reversal in response to miR-186 was mediated by Twist1. Collectively, these findings implicate miR-186 as an attractive candidate for overcoming chemoresistance in ovarian cancer therapy.
@Copyright Harbin Medical University
　The 2nd Affiliated Hospital of Harbin Medical University
　 备案号：鲁ICP备2022025566号-3